Metabolomic Strategy for Studying the Intervention and the Synergistic Effects of the Shexiang Baoxin Pill for Treating Myocardial Infarction in Rats

<table>The six biomarkers that were differently regulated between the SBP- and SFSBP-treated groups. *<i>P</i> &lt; 0.05 and **<i>P </i>&lt; 0.01 when compared with the MI group; <sup>#</sup><i>P </i>&lt; 0.05 and <sup>##</sup>P &lt; 0.01 when compared with the sham group. The number on the <i>y-axis </i>represents the peak areas of these biomarkers. </table>

Evidence-Based Complementary and Alternative Medicine

fig8

Figure 8

Figure 8: Metabolomic Strategy for Studying the Intervention and the Synergistic Effects of the Shexiang Baoxin Pill for Treating Myocardial Infarction in Rats 

Figure 8 | Metabolomic Strategy for Studying the Intervention and the Synergistic Effects of the Shexiang Baoxin Pill for Treating Myocardial Infarction in Rats 